Jefferies Financial Group’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-599,042
Closed -$3.25M 1951
2024
Q4
$3.25M Sell
599,042
-23,431
-4% -$143K 0.02% 504
2024
Q3
$4.49M Buy
622,473
+330,348
+113% +$3.02M 0.03% 341
2024
Q2
$3.17M Buy
292,125
+54,056
+23% +$693K 0.03% 416
2024
Q1
$4.46M Buy
238,069
+109,269
+85% +$2.52M 0.04% 329
2023
Q4
$2.79M Buy
128,800
+104,800
+437% +$2.08M 0.02% 584
2023
Q3
$494K Buy
+24,000
New +$693K ﹤0.01% 1065
2023
Q1
Sell
-13,750
Closed -$524K 1950
2022
Q4
$524K Buy
+13,750
New +$525K ﹤0.01% 1042

Other funds holding SAGE

Jefferies Financial Group's SAGE Position: Q1 2025 in Review

Jefferies Financial Group sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 599,042 shares — an estimated $3.25M sold.

Jefferies Financial Group first reported a position in SAGE in Q4 2022 and held it in 7 quarters. The position peaked at $4.49M in Q3 2024. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Jefferies Financial Group reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 599,042 Sage Therapeutics shares in Q1 2025, an estimated $3.25M.
  • Jefferies Financial Group first reported a position in Sage Therapeutics in Q4 2022 and held it in 7 quarters.
  • Jefferies Financial Group's Sage Therapeutics position peaked at $4.49M in Q3 2024.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Jefferies Financial Group's 13F filing for Q1 2025, filed 8 May 2025.